ARV-766 PROTAC: first results will be announced at 2024 ASCO congress next week

[Maxone73]

You can't be distracted! I turn my head for a second and ARV-766 trial has got some results to post!

I will be traveling on monday, but I will try to check if those data are good!

markets.businessinsider.com...

[God_Loves_Me]

my believe ARV-766 will not work who failed zytiga (Abiraterone acetate) in past

Source link :

scr.zacks.com/news/news-det...

Here is the screenshot from data perspective, They did not treat anyone who failed zytiga

check the row that said " prior Abiraterone" it is 0%. It means to me they did not treat who failed zytiga

Am i correct ? Please help me to understand as well.

ARV 766

[Maxone73 in reply to God_Loves_Me]

I think you are right, but I don't know if it's because it fails to treat them or because they wanted a direct comparison with Affirm and Prevail trials

[Maxone73 in reply to God_Loves_Me]

Got it now!

"AUA 2024: ARV-766, a PROTAC Androgen Receptor Degrader, Combined with Abiraterone in Novel Hormonal Agent (NHA)-Naïve Metastatic Prostate Cancer: Phase 1 Cohort (Part C) of a Phase 1/2 Study"

It's + Abiraterone in the study and it's NHA naive....so no previous Abi

Check it here: urotoday.com/conference-hig...

[God_Loves_Me in reply to Maxone73]

Nice Feels so good Here is the trial URL

clinicaltrials.gov/study/NC...

[rsgdmd]

I was in part 2 of the trial, 300mg. Great early results with PSA reduction of 60% at 4 weeks. Unfortunately, PSA then began to rise and ended trial participation when PSA kept rising & scans showed progression. I think the idea of hitting the cancer with multiple hammers all at once is the way to go. I believe (& my Dr. agrees) that ARV-766 killed a subset of cancer cells, which left room for those that survived to grow (less competition for resources, etc). I think same occurred (for me) with Pluvicto.

[God_Loves_Me in reply to rsgdmd]

How many PSA test done before you end the trial ?

[rsgdmd in reply to God_Loves_Me]

3, all with significant increases, plus evidence of progression on scans.